Gilead's HIV Treatments Boost Stock, Earnings

Gilead Sciences stock surged by over three percent today, driven by positive news including successful late-stage HIV treatment trial results, UK regulatory approval for a new HIV drug, and a new pricing agreement with the US government. The companys strong earnings and raised full-year profit outlook have contributed to a thirty-five percent stock increase since the start of the year, now trading near its fifty-two-week high.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.